Andrew Belch

Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group

C. Tom Kouroukis, Andrew Belch, Michael Crump et al. · Journal of Clinical Oncology · 2003 · 280 citations

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

Thierry Façon, Meletios Α. Dimopoulos, Nathalie Meuleman et al. · Leukemia · 2019 · 214 citations · Full text

Simplified Frailty Scale, Prognosis, Transplantation Medicine +17

An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma.

Robert Marcus, Kevin Imrie, Andrew Belch et al. · Ghent University Academic Bibliography (Ghent University) · 2003 · 42 citations

Lymphoid Neoplasia, International Multi-centre, Medicine +9

Phase II Trial of Bortezomib in Mantle Cell Lymphoma.

Andrew Belch, C. Tom Kouroukis, Michael Crump et al. · Blood · 2004 · 33 citations

Origin of leukemic relapse after bone marrow transplantation detected by restriction fragment length polymorphism.

Mark D. Minden, Hans A. Messner, Andrew Belch · Journal of Clinical Investigation · 1985 · 31 citations · Full text

Hematological Malignancy, Transplantation, Marrow Transplantation +14